Results 91 to 100 of about 23,011 (205)
Anaplastic Large Cell Lymphoma in the Setting of Penile Implant
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT Breast‐implant‐associated anaplastic large cell lymphoma can develop in the setting of an inflatable penile prosthesis.
Michael Lauricella +2 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.Chest contrast‐enhanced computed tomography. A slightly enhanced solid intraluminal mass is observed in the left (green arrow) and right (yellow arrow) main pulmonary arteries. ABSTRACT We report a case of pulmonary artery intimal sarcoma successfully treated with surgical resection followed by weekly paclitaxel.
Fumitaka Endo +6 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 8, August 2026.ABSTRACT The third reported case of synchronous colorectal adenocarcinoma and EBV‐positive DLBCL in an 87‐year‐old patient confirms the rarity of this synchronous tumor. Despite segmental resection, the patient died from postoperative complications, highlighting the need for multidisciplinary research into pathogenesis and management.
Fen Liu +3 more
wiley +1 more source
HemaSphere, Volume 10, Issue 8, August 2026.Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo +21 more
wiley +1 more source
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT ALK‐negative anaplastic large cell lymphoma (ALCL) is a rare primary central nervous system lymphoma (PCNSL). Although DUSP22 rearrangement is considered favorable in systemic ALK‐negative ALCL, survival remains poor in PCNSL. We report a case of PCNSL ALK‐negative ALCL with DUSP22‐IRF4 rearrangement and an unusual gain of the ALK gene (2p23),
Sindu Iska +5 more
wiley +1 more source
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
MedComm, Volume 7, Issue 8, August 2026.The graphic summarizes the design principles, intracellular trafficking, clinical progress, challenges, and future directions of antibody–drug conjugates (ADCs) and peptide–drug conjugates (PDCs). ADCs consist of a tumor‐targeting antibody, a chemical linker, and a potent payload, whereas PDCs use peptide ligands to deliver cytotoxic, radionuclide, or ...
Ruxi Zheng +9 more
wiley +1 more source
Current and Future Developments in the Treatment of CD30+ Lymphomas [PDF]
European Medical Journal Oncology, 2015 CD30 is a cell membrane protein expressed on the surface of a range of lymphomas, which has important diagnostic, pathogenic, and prognostic roles. The most common CD30+ lymphomas are Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL), but
Lena Specht, Christian Gisselbrecht
doaj
Human Pharmacokinetic Prediction of Antibody‐Drug Conjugates Using Human FcRn Transgenic Mice
Clinical and Translational Science, Volume 19, Issue 8, August 2026.ABSTRACT Antibody‐drug conjugates (ADCs) have progressed significantly in recent years, particularly in the oncology field. However, predicting human pharmacokinetics (PK) of ADCs in the early stages of drug development remains challenging. Human neonatal Fc receptor (FcRn) transgenic mice have been established as a reliable pre‐clinical PK model for ...
Keitaro Nakagawa, Kenta Haraya
wiley +1 more source
Histopathology, Volume 89, Issue 2, Page 303-311, August 2026.Immunohistochemical analysis of transcription factors in GCNIS associated with pure EC and YST suggests that reprogramming to non‐seminoma occurs outside the spermatogonial niche. In these tumors, reprogramming may occur immediately upon invasion of the stroma or within seminiferous tubules but outside the spermatogonial niche (i.e., in intratubular ...
Daisy Maharjan +15 more
wiley +1 more source
4‐1BB Expression and Signaling Regulates MAIT Cell Activation and Effector Functions
Immunology &Cell Biology, Volume 104, Issue 7, Page 686-699, August 2026.4‐1BB is a highly expressed TNFRSF co‐stimulatory receptor on MAIT cells upon activation. Expression and signaling via 4‐1BB enhance activation and provide co‐stimulation, boosting MAIT cell effector responses to TCR‐mediated activation. ABSTRACT Mucosal associated invariant T (MAIT) cells are abundant unconventional T cells that recognize microbe ...
Lamichhane R +8 more
wiley +1 more source